Xiaobao Bi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaobao Bi has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Chuan-Fa Liu
School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
11 shared publications Dechun Yang
Zhejiang University of Technology
6 shared publicationsJuan Yin
Zhejiang Yangshengtang Institute of Natural Medication Co., Ltd Hangzhou 310013 China
6 shared publications- Bang-Ce Ye
Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology , Shanghai 200237
4 shared publications - James P. Tam
School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore
4 shared publications Xinya Hemu
School of Traditional Chinese Pharmacy China Pharmaceutical University Nanjing, Jiangsu China
4 shared publications
Latest Publications
- 8 October 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (41) , 27931-27948
Bioorthogonal Assembly of Cell-Nanoparticle Hybrids Enables Synergistic Cancer Therapy
Integrating nanoparticles (NPs) with living cells into a unified therapeutic system remains a major methodological challenge. Here, we describe a robust and modular bioorthogonal strategy for constructing cell-nanoparticle hybrids (CNHs) via sequential thiazolidine formation and SpyCatcher/SpyTag ligation. This two-step chemical assembly enables highly specific and covalent conjugation of structurally diverse NP payloads─including ferritin nanocages, lipid micelles, and amphiphilic polymers─onto aldehyde-presenting cell surfaces without genetic modification, ensuring broad applicability while preserving cellular functionality. The resulting CNHs exhibit enhanced nanoparticle retention and tumor penetration both in vitro and in vivo. In a colorectal cancer xenograft model, CNHs demonstrate superior antitumor efficacy compared with free drugs, unconjugated NPs, or unmodified macrophages. Mechanistic studies indicate that the enhanced tumor inhibition arises from the combined effects of chemotherapeutic drug-loaded NPs and the intrinsic properties of macrophages. Collectively, these results demonstrate a versatile chemical framework for bioorthogonal cell-nanoparticle assembly and the rational design of functional living hybrid systems.
- 8 October 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (41) , 27931-27948
Bioorthogonal Assembly of Cell-Nanoparticle Hybrids Enables Synergistic Cancer Therapy
Integrating nanoparticles (NPs) with living cells into a unified therapeutic system remains a major methodological challenge. Here, we describe a robust and modular bioorthogonal strategy for constructing cell-nanoparticle hybrids (CNHs) via sequential thiazolidine formation and SpyCatcher/SpyTag ligation. This two-step chemical assembly enables highly specific and covalent conjugation of structurally diverse NP payloads─including ferritin nanocages, lipid micelles, and amphiphilic polymers─onto aldehyde-presenting cell surfaces without genetic modification, ensuring broad applicability while preserving cellular functionality. The resulting CNHs exhibit enhanced nanoparticle retention and tumor penetration both in vitro and in vivo. In a colorectal cancer xenograft model, CNHs demonstrate superior antitumor efficacy compared with free drugs, unconjugated NPs, or unmodified macrophages. Mechanistic studies indicate that the enhanced tumor inhibition arises from the combined effects of chemotherapeutic drug-loaded NPs and the intrinsic properties of macrophages. Collectively, these results demonstrate a versatile chemical framework for bioorthogonal cell-nanoparticle assembly and the rational design of functional living hybrid systems.
- 1 July 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (7) , 1463-1474
SpyCatcher-Engineered Ferritin Nanocages Enable Dual-Receptor Targeting for Enhanced Glioma Therapy
Human heavy-chain ferritin (FTn) that can bind to transferrin receptor 1 (TfR1) has emerged as a promising platform for brain tumor drug delivery. However, the broad expression of TfR1 in normal tissues fundamentally limits tumor selectivity and therapeutic precision. Herein, we engineered a dual-receptor-targeting FTn nanoplatform by site-specifically conjugating an epidermal growth factor receptor (EGFR) affibody to FTn using the SpyCatcher/SpyTag system, generating FTn-EGFRAfb nanoparticles. This modular strategy preserves FTn architecture and stability while enabling precise ligand conjugation. Doxorubicin (DOX) was efficiently encapsulated via temperature-controlled loading to obtain DOX@FTn-EGFRAfb with high protein recovery, pH-responsive drug release, and strong stability. In vitro, the nanoparticles showed enhanced uptake and cytotoxicity in TfR1/EGFR double-positive U87 glioma cells. In an orthotopic U87 glioma mouse model, DOX@FTn-EGFRAfb significantly inhibited tumor growth and prolonged survival without obvious systemic toxicity. This work presents a versatile protein-engineering strategy for dual-targeted glioblastoma drug delivery.
- 1 July 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (7) , 1463-1474
SpyCatcher-Engineered Ferritin Nanocages Enable Dual-Receptor Targeting for Enhanced Glioma Therapy
Human heavy-chain ferritin (FTn) that can bind to transferrin receptor 1 (TfR1) has emerged as a promising platform for brain tumor drug delivery. However, the broad expression of TfR1 in normal tissues fundamentally limits tumor selectivity and therapeutic precision. Herein, we engineered a dual-receptor-targeting FTn nanoplatform by site-specifically conjugating an epidermal growth factor receptor (EGFR) affibody to FTn using the SpyCatcher/SpyTag system, generating FTn-EGFRAfb nanoparticles. This modular strategy preserves FTn architecture and stability while enabling precise ligand conjugation. Doxorubicin (DOX) was efficiently encapsulated via temperature-controlled loading to obtain DOX@FTn-EGFRAfb with high protein recovery, pH-responsive drug release, and strong stability. In vitro, the nanoparticles showed enhanced uptake and cytotoxicity in TfR1/EGFR double-positive U87 glioma cells. In an orthotopic U87 glioma mouse model, DOX@FTn-EGFRAfb significantly inhibited tumor growth and prolonged survival without obvious systemic toxicity. This work presents a versatile protein-engineering strategy for dual-targeted glioblastoma drug delivery.
- Open Access
- 25 March 2026
- Published by Elsevier in SSRN Electronic Journal
SpyCatcher-Engineered Ferritin Nanocages Enable Dual-Receptor Targeting for Enhanced Glioma Therapy
Owing to its endogenous origin, well-defined nanocage architecture, and intrinsic affinity for transferrin receptor 1 (TfR1), human heavy-chain ferritin (HFn) has emerged as a promising platform for brain tumor drug delivery. However, the broad expression of TfR1 in normal tissues fundamentally limits tumor selectivity and therapeutic precision. Herein, we report a genetically engineered ferritin-based nanoplatform that achieves hierarchical dual-receptor targeting to address this challenge. By integrating the SpyCatcher/SpyTag conjugation system, ferritin nanocages were covalently and site-specifically functionalized with an epidermal growth factor receptor (EGFR) affibody, yielding FTn-EGFRAfb nanoparticles capable of coordinating TfR1-mediated transport with EGFR-driven tumor cell uptake. This modular engineering strategy preserves the native ferritin architecture and colloidal stability while enabling precise and irreversible ligand conjugation. Doxorubicin was efficiently encapsulated via a temperature-controlled loading approach, affording DOX@FTn-EGFRAfb with high protein recovery, pH-responsive drug release, and excellent stability. In vitro studies demonstrated significantly enhanced cellular uptake and cytotoxicity toward EGFR-positive U87 glioma cells compared with non-targeted ferritin formulations. In an orthotopic U87 glioma mouse model, DOX@FTn-EGFRAfb markedly inhibited tumor progression and prolonged survival without evident systemic toxicity. Collectively, this work establishes a modular protein-engineering strategy that enables hierarchical TfR1/EGFR dual targeting while preserving the native architecture and transport advantages of ferritin nanocages. This platform provides a versatile framework for precision drug delivery in glioblastoma and other brain tumor therapies.
- 25 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSpyCatcher-Engineered Ferritin Nanocages Enable Dual-Receptor Targeting for Enhanced Glioma Therapy
Owing to its endogenous origin, well-defined nanocage architecture, and intrinsic affinity for transferrin receptor 1 (TfR1), human heavy-chain ferritin (HFn) has emerged as a promising platform for brain tumor drug delivery. However, the broad expression of TfR1 in normal tissues fundamentally limits tumor selectivity and therapeutic precision. Herein, we report a genetically engineered ferritin-based nanoplatform that achieves hierarchical dual-receptor targeting to address this challenge. By integrating the SpyCatcher/SpyTag conjugation system, ferritin nanocages were covalently and site-specifically functionalized with an epidermal growth factor receptor (EGFR) affibody, yielding FTn-EGFRAfb nanoparticles capable of coordinating TfR1-mediated transport with EGFR-driven tumor cell uptake. This modular engineering strategy preserves the native ferritin architecture and colloidal stability while enabling precise and irreversible ligand conjugation. Doxorubicin was efficiently encapsulated via a temperature-controlled loading approach, affording DOX@FTn-EGFRAfb with high protein recovery, pH-responsive drug release, and excellent stability. In vitro studies demonstrated significantly enhanced cellular uptake and cytotoxicity toward EGFR-positive U87 glioma cells compared with non-targeted ferritin formulations. In an orthotopic U87 glioma mouse model, DOX@FTn-EGFRAfb markedly inhibited tumor progression and prolonged survival without evident systemic toxicity. Collectively, this work establishes a modular protein-engineering strategy that enables hierarchical TfR1/EGFR dual targeting while preserving the native architecture and transport advantages of ferritin nanocages. This platform provides a versatile framework for precision drug delivery in glioblastoma and other brain tumor therapies.
- 25 October 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (44) , 30332-30344
Engineered Outer Membrane Vesicles as Nanosized Immune Cell Engagers for Enhanced Solid Tumor Immunotherapy
Although tumor immunotherapy has achieved significant success in recent years, tackling solid tumors remains a formidable challenge. Here, we present an approach that utilizes outer membrane vesicles (OMVs) from bacterial cells as scaffolds to engage immune cells in solid tumor immunotherapy. Two types of nanobodies targeting CD47/SIRPα and PD-1/PD-L1 pathways were simultaneously conjugated onto the surfaces of the OMVs in divalent and trivalent forms using orthogonal SpyCatcher-SpyTag and SnoopCatcher-SnoopTag chemistry. This resulted in the generation of an OMV-based nanosized immune cell engager (OMV-NICE) with dual-targeting abilities. In vitro assays confirmed the retention of the function of the two nanobodies on the OMV-NICE, as evidenced by the synergistically enhanced macrophage phagocytosis and T cell cytotoxicity against tumor cells. In vivo studies using a B16-F10 melanoma mouse model also revealed the superior antitumor activity of OMV-NICE compared to those of unconjugated nanobodies and OMVs alone. Subsequent mechanistic investigations further supported the enhanced recruitment of macrophages and T cells to the tumor region by OMV-NICE. Overall, this work expands the current repertoire of immune cell engagers, and the developed OMV-NICE platform holds great promise for broad applications, particularly in solid tumor immunotherapy.
- 25 October 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (44) , 30332-30344
Engineered Outer Membrane Vesicles as Nanosized Immune Cell Engagers for Enhanced Solid Tumor Immunotherapy
Although tumor immunotherapy has achieved significant success in recent years, tackling solid tumors remains a formidable challenge. Here, we present an approach that utilizes outer membrane vesicles (OMVs) from bacterial cells as scaffolds to engage immune cells in solid tumor immunotherapy. Two types of nanobodies targeting CD47/SIRPα and PD-1/PD-L1 pathways were simultaneously conjugated onto the surfaces of the OMVs in divalent and trivalent forms using orthogonal SpyCatcher-SpyTag and SnoopCatcher-SnoopTag chemistry. This resulted in the generation of an OMV-based nanosized immune cell engager (OMV-NICE) with dual-targeting abilities. In vitro assays confirmed the retention of the function of the two nanobodies on the OMV-NICE, as evidenced by the synergistically enhanced macrophage phagocytosis and T cell cytotoxicity against tumor cells. In vivo studies using a B16-F10 melanoma mouse model also revealed the superior antitumor activity of OMV-NICE compared to those of unconjugated nanobodies and OMVs alone. Subsequent mechanistic investigations further supported the enhanced recruitment of macrophages and T cells to the tumor region by OMV-NICE. Overall, this work expands the current repertoire of immune cell engagers, and the developed OMV-NICE platform holds great promise for broad applications, particularly in solid tumor immunotherapy.
- Open Access
- 19 September 2024
- Published by Wiley in Advanced Science
- Vol. 11 (42) , e2408180
Repurposing Copper(II)/THPTA as A Bioorthogonal Catalyst for Thiazolidine Bond Cleavage
Metal‐mediated chemical transformations are promising approaches to manipulate and regulate proteins in fundamental biological research and therapeutic development. Nevertheless, unlike bond‐forming reactions, the exploration of selective bond cleavage reactions catalyzed by metals that are fully compatible with proteins and living systems remains relatively limited. Here, it is reported that Copper(II)/tris(3‐hydroxypropyltriazolylmethyl)amine (THPTA), commonly used in copper‐catalyzed azide‐alkyne cycloaddition (CuAAC) reaction, can be repurposed as a new bioorthogonal catalyst for thiazolidine (Thz) bond cleavage. This process liberates an α‐oxo‐aldehyde group under physiological conditions, without requiring additional additives. To showcase the utility of this method, this simple catalyst system is coupled with genetic code expansion technology to achieve on‐demand activation of genetically encoded Thz‐caged α‐oxo‐aldehydes, enabling further functionalization of proteins. For the first time, this cell‐compatible Thz uncaging reaction allows for the site‐specific installation of α‐oxo‐aldehydes at the internal positions of proteins in phage and bacterial surface display systems, expanding the chemical space of proteins. Overall, this study expands the toolkit of bioorthogonal catalysts and paves the way for metal‐promoted chemical reactions in living systems, potentially benefiting various applications in the future.
- 19 September 2024
- Published by Wiley in Advanced Science
- Vol. 11 (42) , e2408180
Open AccessRepurposing Copper(II)/THPTA as A Bioorthogonal Catalyst for Thiazolidine Bond Cleavage
Metal‐mediated chemical transformations are promising approaches to manipulate and regulate proteins in fundamental biological research and therapeutic development. Nevertheless, unlike bond‐forming reactions, the exploration of selective bond cleavage reactions catalyzed by metals that are fully compatible with proteins and living systems remains relatively limited. Here, it is reported that Copper(II)/tris(3‐hydroxypropyltriazolylmethyl)amine (THPTA), commonly used in copper‐catalyzed azide‐alkyne cycloaddition (CuAAC) reaction, can be repurposed as a new bioorthogonal catalyst for thiazolidine (Thz) bond cleavage. This process liberates an α‐oxo‐aldehyde group under physiological conditions, without requiring additional additives. To showcase the utility of this method, this simple catalyst system is coupled with genetic code expansion technology to achieve on‐demand activation of genetically encoded Thz‐caged α‐oxo‐aldehydes, enabling further functionalization of proteins. For the first time, this cell‐compatible Thz uncaging reaction allows for the site‐specific installation of α‐oxo‐aldehydes at the internal positions of proteins in phage and bacterial surface display systems, expanding the chemical space of proteins. Overall, this study expands the toolkit of bioorthogonal catalysts and paves the way for metal‐promoted chemical reactions in living systems, potentially benefiting various applications in the future.
- Open Access
- 17 September 2024
- Published by Wiley in Chemistry – A European Journal
- Vol. 30 (56) , e202402272
Recent Toolboxes for Chemoselective Dual Modifications of Proteins
Site‐selective chemical modifications of proteins have emerged as a potent technology in chemical biology, materials science, and medicine, facilitating precise manipulation of proteins with tailored functionalities for basic biology research and developing innovative therapeutics. Compared to traditional recombinant expression methods, one of the prominent advantages of chemical protein modification lies in its capacity to decorate proteins with a wide range of functional moieties, including non‐genetically encoded ones, enabling the generation of novel protein conjugates with enhanced or previously unexplored properties. Among these, approaches for dual or multiple modifications of proteins are increasingly garnering attention, as it has been found that single modification of proteins is inadequate to meet current demands. Therefore, in light of the rapid developments in this field, this review provides a timely and comprehensive overview of the latest advancements in chemical and biological approaches for dual functionalization of proteins. It further discusses their advantages, limitations, and potential future directions in this relatively nascent area.
- 17 September 2024
- Published by Wiley in Chemistry – A European Journal
- Vol. 30 (56) , e202402272
Open AccessRecent Toolboxes for Chemoselective Dual Modifications of Proteins
Site‐selective chemical modifications of proteins have emerged as a potent technology in chemical biology, materials science, and medicine, facilitating precise manipulation of proteins with tailored functionalities for basic biology research and developing innovative therapeutics. Compared to traditional recombinant expression methods, one of the prominent advantages of chemical protein modification lies in its capacity to decorate proteins with a wide range of functional moieties, including non‐genetically encoded ones, enabling the generation of novel protein conjugates with enhanced or previously unexplored properties. Among these, approaches for dual or multiple modifications of proteins are increasingly garnering attention, as it has been found that single modification of proteins is inadequate to meet current demands. Therefore, in light of the rapid developments in this field, this review provides a timely and comprehensive overview of the latest advancements in chemical and biological approaches for dual functionalization of proteins. It further discusses their advantages, limitations, and potential future directions in this relatively nascent area.
- Open Access
- 21 August 2024
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 10 (9) , 1742-1754
Peptide and Protein Cysteine Modification Enabled by Hydrosulfuration of Ynamide
Efficient functionalization of peptides and proteins has widespread applications in chemical biology and drug discovery. However, the chemoselective and site-selective modification of proteins remains a daunting task. Herein, a highly efficient chemo-, regio-, and stereoselective hydrosulfuration of ynamide was identified as an efficient method for the precise modification of peptides and proteins by uniquely targeting the thiol group of cysteine (Cys) residues. This novel method could be facilely operated in aqueous buffer and was fully compatible with a wide range of proteins, including small model proteins and large full-length antibodies, without compromising their integrity and functions. Importantly, this reaction provides the Z-isomer of the corresponding conjugates exclusively with superior stability, offering a precise approach to peptide and protein therapeutics. The potential application of this method in peptide and protein chemical biology was further exemplified by Cys-bioconjugation with a variety of ynamide-bearing functional molecules such as small molecule drugs, fluorescent/affinity tags, and PEG polymers. It also proved efficient in redox proteomic analysis through Cys-alkenylation. Overall, this study provides a novel bioorthogonal tool for Cys-specific functionalization, which will find broad applications in the synthesis of peptide/protein conjugates.
- 21 August 2024
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 10 (9) , 1742-1754
Open AccessPeptide and Protein Cysteine Modification Enabled by Hydrosulfuration of Ynamide
Efficient functionalization of peptides and proteins has widespread applications in chemical biology and drug discovery. However, the chemoselective and site-selective modification of proteins remains a daunting task. Herein, a highly efficient chemo-, regio-, and stereoselective hydrosulfuration of ynamide was identified as an efficient method for the precise modification of peptides and proteins by uniquely targeting the thiol group of cysteine (Cys) residues. This novel method could be facilely operated in aqueous buffer and was fully compatible with a wide range of proteins, including small model proteins and large full-length antibodies, without compromising their integrity and functions. Importantly, this reaction provides the Z-isomer of the corresponding conjugates exclusively with superior stability, offering a precise approach to peptide and protein therapeutics. The potential application of this method in peptide and protein chemical biology was further exemplified by Cys-bioconjugation with a variety of ynamide-bearing functional molecules such as small molecule drugs, fluorescent/affinity tags, and PEG polymers. It also proved efficient in redox proteomic analysis through Cys-alkenylation. Overall, this study provides a novel bioorthogonal tool for Cys-specific functionalization, which will find broad applications in the synthesis of peptide/protein conjugates.
- Open Access
- 7 June 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Cu(II)/THPTA-Mediated Thiazolidine Deprotection for Living Phages and Cell Surfaces Labeling
Incorporating unnatural bioorthogonal groups into peptides and proteins offers an excellent opportunity to endow them with new properties in a precise and controlled manner. Among these, the α-oxo aldehyde group is particularly suitable for the post-functionalization of peptides and proteins due to its versatility and stability in aqueous buffers. However, the facile and site-specific incorporation of α-oxo aldehyde into proteins, especially in living systems, remains a long-lasting challenge. Here, we describe a novel Cu(II)/THPTA-Mediated Thiazolidine Deprotection (CUT-METHOD) strategy for post-installation of a highly-active α-oxo aldehyde moiety, which is released from a thiazolidine ring borne by a genetically encoded unnatural amino acid ThzK. This reaction is performed under physiological conditions, thereby enabling the chemoselective and site-specific modification of proteins via oxime ligation without compromising their integrity and function. To validate its versatility, we successfully performed site-specific incorporation of α-oxo aldehyde into recombinant proteins and those displayed on M13 filamentous bacteriophage particles and bacterial cell surfaces. In addition, by leveraging Spycatcher/Spytag chemistry and oxime ligation, the bacterial cells bearing aldehyde generated via the CUT-METHOD could be simultaneously decorated with two distinct functional molecules, providing a novel one-pot dual labeling platform for the construction of living bacterial cell-based cancer targeting systems. Put together, we have demonstrated that the CUT-METHOD strategy is a significant addition to the current bioorthogonal chemistry toolbox with broad applications anticipated in the near future.
- 7 June 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessCu(II)/THPTA-Mediated Thiazolidine Deprotection for Living Phages and Cell Surfaces Labeling
Incorporating unnatural bioorthogonal groups into peptides and proteins offers an excellent opportunity to endow them with new properties in a precise and controlled manner. Among these, the α-oxo aldehyde group is particularly suitable for the post-functionalization of peptides and proteins due to its versatility and stability in aqueous buffers. However, the facile and site-specific incorporation of α-oxo aldehyde into proteins, especially in living systems, remains a long-lasting challenge. Here, we describe a novel Cu(II)/THPTA-Mediated Thiazolidine Deprotection (CUT-METHOD) strategy for post-installation of a highly-active α-oxo aldehyde moiety, which is released from a thiazolidine ring borne by a genetically encoded unnatural amino acid ThzK. This reaction is performed under physiological conditions, thereby enabling the chemoselective and site-specific modification of proteins via oxime ligation without compromising their integrity and function. To validate its versatility, we successfully performed site-specific incorporation of α-oxo aldehyde into recombinant proteins and those displayed on M13 filamentous bacteriophage particles and bacterial cell surfaces. In addition, by leveraging Spycatcher/Spytag chemistry and oxime ligation, the bacterial cells bearing aldehyde generated via the CUT-METHOD could be simultaneously decorated with two distinct functional molecules, providing a novel one-pot dual labeling platform for the construction of living bacterial cell-based cancer targeting systems. Put together, we have demonstrated that the CUT-METHOD strategy is a significant addition to the current bioorthogonal chemistry toolbox with broad applications anticipated in the near future.
- Open Access
- 8 June 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (26) , 7334-7345
Catalyst-free thiazolidine formation chemistry enables the facile construction of peptide/protein–cell conjugates (PCCs) at physiological pH
Although numerous genetic, chemical, and physical strategies have been developed to remodel the cell surface landscape for basic research and the development of live cell-based therapeutics, new chemical modification strategies capable of decorating cells with various genetically/non-genetically encodable molecules are still urgently needed. Herein, we describe a remarkably simple and robust chemical strategy for cell surface modifications by revisiting the classical thiazolidine formation chemistry. Cell surfaces harbouring aldehydes can be chemoselectively conjugated with molecules containing a 1,2-aminothiol moiety at physiological pH without the need to use any toxic catalysts and complicated chemical synthesis. Through the combined use of thiazolidine formation and the SpyCatcher–SpyTag system, we have further developed a SpyCatcher–SpyTag Chemistry Assisted Cell Surface Engineering (SpyCASE) platform, providing a modular approach for the construction of large protein–cell conjugates (PCCs) in their native state. Thiazolidine-bridged molecules can also be detached from the surface again through a biocompatible Pd-catalyzed bond scission reaction, enabling reversible modification of living cell surfaces. In addition, this approach allows us to modulate specific cell–cell interactions and generate NK cell-based PCCs to selectively target/kill several EGFR-positive cancer cells in vitro. Overall, this study provides an underappreciated but useful chemical tool to decorate cells with tailor-made functionalities.
- 8 June 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 14 (26) , 7334-7345
Open AccessCatalyst-free thiazolidine formation chemistry enables the facile construction of peptide/protein–cell conjugates (PCCs) at physiological pH
Although numerous genetic, chemical, and physical strategies have been developed to remodel the cell surface landscape for basic research and the development of live cell-based therapeutics, new chemical modification strategies capable of decorating cells with various genetically/non-genetically encodable molecules are still urgently needed. Herein, we describe a remarkably simple and robust chemical strategy for cell surface modifications by revisiting the classical thiazolidine formation chemistry. Cell surfaces harbouring aldehydes can be chemoselectively conjugated with molecules containing a 1,2-aminothiol moiety at physiological pH without the need to use any toxic catalysts and complicated chemical synthesis. Through the combined use of thiazolidine formation and the SpyCatcher–SpyTag system, we have further developed a SpyCatcher–SpyTag Chemistry Assisted Cell Surface Engineering (SpyCASE) platform, providing a modular approach for the construction of large protein–cell conjugates (PCCs) in their native state. Thiazolidine-bridged molecules can also be detached from the surface again through a biocompatible Pd-catalyzed bond scission reaction, enabling reversible modification of living cell surfaces. In addition, this approach allows us to modulate specific cell–cell interactions and generate NK cell-based PCCs to selectively target/kill several EGFR-positive cancer cells in vitro. Overall, this study provides an underappreciated but useful chemical tool to decorate cells with tailor-made functionalities.
- 19 July 2020
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 92 (18) , 12460-12466
Tagging Transferrin Receptor with a Disulfide FRET Probe To Gauge the Redox State in Endosomal Compartments
Although the basic process of receptor-mediated endocytosis (RME) is well established, certain specific aspects, like the endosomal redox state, remain less characterized. Previous studies used chemically labeled ligands or antibodies with a FRET (Fluorescence Resonance Energy Transfer) probe to gauge the redox activity of the endocytic pathway, with a limitation being their inability to track the apo receptor. New tools that allow direct labeling of a cell-surface receptor with synthetic probes would aid in the study of its endocytic pathway and function. Herein, we use a peptide ligase, butelase 1, to label the human transferrin receptor 1 (TfR1) in established human cell lines with a designer disulfide FRET probe. This strategy enables us to obtain real-time live cell imaging of redox states in TfR1-mediated endocytosis, attesting a reducing environment in the endoso-mal compartments and the dynamics of TfR1 trafficking. A better understanding of endocytosis of different cell surface receptors has implications in designing strategies that hijack this natural process for intracellular drug delivery.
- 19 July 2020
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 92 (18) , 12460-12466
Tagging Transferrin Receptor with a Disulfide FRET Probe To Gauge the Redox State in Endosomal Compartments
Although the basic process of receptor-mediated endocytosis (RME) is well established, certain specific aspects, like the endosomal redox state, remain less characterized. Previous studies used chemically labeled ligands or antibodies with a FRET (Fluorescence Resonance Energy Transfer) probe to gauge the redox activity of the endocytic pathway, with a limitation being their inability to track the apo receptor. New tools that allow direct labeling of a cell-surface receptor with synthetic probes would aid in the study of its endocytic pathway and function. Herein, we use a peptide ligase, butelase 1, to label the human transferrin receptor 1 (TfR1) in established human cell lines with a designer disulfide FRET probe. This strategy enables us to obtain real-time live cell imaging of redox states in TfR1-mediated endocytosis, attesting a reducing environment in the endoso-mal compartments and the dynamics of TfR1 trafficking. A better understanding of endocytosis of different cell surface receptors has implications in designing strategies that hijack this natural process for intracellular drug delivery.